Lessons Learned
gastrointestinal stromal tumors
GIST, GASTROINTESTINAL STROMAL TUMORS
This open-label, phase I/II bridging study indicated that avapritinib was safe and tolerable for patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).Avapritinib provided pronounced anti-tumor activity in patients with PDGFRA D842V mutations and in patients without such mutations but receiving fourth- or later-line treatment.Avapritinib was approved in China for the treatment of PDGFRA D842V-mutant GIST based on these and the global NAVIGATOR findings.